Xbrane Biopharma マネジメント

マネジメント基準チェック /44

Xbrane Biopharmaの CEO はMartin Amarkで、 Jan2015年に任命され、の在任期間は 9.83年です。の年間総報酬はSEK 3.36Mで、 77%給与と23%のボーナス（会社の株式とオプションを含む）で構成されています。は、会社の株式の0.012%を直接所有しており、その価値はSEK 37.49K 。経営陣と取締役会の平均在任期間はそれぞれ9.8年と4.5年です。

主要情報

Martin Amark

最高経営責任者

SEK 3.4m

報酬総額

CEO給与比率	77.0%
CEO在任期間	9.8yrs
CEOの所有権	0.01%
経営陣の平均在職期間	9.8yrs
取締役会の平均在任期間	4.5yrs

経営陣の近況

Recent updates

Even With A 30% Surge, Cautious Investors Are Not Rewarding Xbrane Biopharma AB (publ)'s (STO:XBRANE) Performance Completely

Sep 30

Market Cool On Xbrane Biopharma AB (publ)'s (STO:XBRANE) Revenues Pushing Shares 34% Lower

Aug 05

Market Might Still Lack Some Conviction On Xbrane Biopharma AB (publ) (STO:XBRANE) Even After 32% Share Price Boost

Jun 21

Xbrane Biopharma AB (publ)'s (STO:XBRANE) Intrinsic Value Is Potentially 28% Above Its Share Price

Feb 10

We Think Xbrane Biopharma (STO:XBRANE) Can Afford To Drive Business Growth

Jan 12

CEO報酬分析

Xbrane Biopharma の収益と比較して、Martin Amark の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Sep 30 2024	n/a	n/a	-SEK 305m
Jun 30 2024	n/a	n/a	-SEK 341m
Mar 31 2024	n/a	n/a	-SEK 361m
Dec 31 2023	SEK 3m	SEK 3m	-SEK 322m
Sep 30 2023	n/a	n/a	-SEK 285m
Jun 30 2023	n/a	n/a	-SEK 246m
Mar 31 2023	n/a	n/a	-SEK 189m
Dec 31 2022	SEK 5m	SEK 2m	-SEK 169m
Sep 30 2022	n/a	n/a	-SEK 146m
Jun 30 2022	n/a	n/a	-SEK 147m
Mar 31 2022	n/a	n/a	-SEK 172m
Dec 31 2021	SEK 4m	SEK 2m	-SEK 183m
Sep 30 2021	n/a	n/a	-SEK 213m
Jun 30 2021	n/a	n/a	-SEK 219m
Mar 31 2021	n/a	n/a	-SEK 215m
Dec 31 2020	SEK 3m	SEK 1m	-SEK 218m
Sep 30 2020	n/a	n/a	-SEK 222m
Jun 30 2020	n/a	n/a	-SEK 210m
Mar 31 2020	n/a	n/a	-SEK 204m
Dec 31 2019	SEK 2m	SEK 1m	-SEK 188m
Sep 30 2019	n/a	n/a	-SEK 154m
Jun 30 2019	n/a	n/a	-SEK 56m
Mar 31 2019	n/a	n/a	-SEK 40m
Dec 31 2018	SEK 1m	SEK 1m	-SEK 13m
Sep 30 2018	n/a	n/a	SEK 30k
Jun 30 2018	n/a	n/a	-SEK 69m
Mar 31 2018	n/a	n/a	-SEK 45m
Dec 31 2017	SEK 1m	SEK 919k	-SEK 45m

報酬と市場: Martinの総報酬 ($USD 303.77K ) は、 Swedish市場 ($USD 235.43K ) の同様の規模の企業の平均とほぼ同じです。

報酬と収益: Martinの報酬は、過去 1 年間の会社の業績と一致しています。

CEO（最高経営責任者

Martin Amark (44 yo)

9.8yrs

在職期間

SEK 3,360,000

報酬

Mr. Martin Amark serves as Chief Executive Officer of Xbrane Biopharma AB (publ) and served as its Head of Investor Relation since February 14, 2019. He has experience from Bain & Co as a Management Consul...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Martin Amark	Chief Executive Officer	9.8yrs	SEK 3.36m	0.012% SEK 37.5k
Siavash Bashiri	COO, Head of Biosimilars & Deputy CEO	9.8yrs	SEK 1.79m	0.0076% SEK 23.1k
Jan-Willem De Gier	Co-Founder	no data	データなし	データなし
Samuel Wagner	Co-Founder & Member of Scientific Advisory Board	16.8yrs	データなし	データなし
Anette Lindqvist	CFO & Head of Investor Relations	3.8yrs	データなし	0.00098% SEK 3.0k
David Vikström	Chief Technology Officer	10.8yrs	データなし	0.0022% SEK 6.6k
Dina Jurman	Head of Clinical Affairs	7.2yrs	データなし	0.000030% SEK 90.9
Anders Wallström	Head of Manufacturing & Supply Chain	5.8yrs	データなし	0.00091% SEK 2.8k
Håkan Yildirim	Head of Intellectual Property	no data	データなし	データなし

9.8yrs

平均在職期間

45.5yo

平均年齢

経験豊富な経営陣: XBRANEの経営陣は経験豊富で経験豊富です（平均在職期間は9.8年）。

取締役

名称	ポジション	在職期間	報酬	所有権
Samuel Wagner	Co-Founder & Member of Scientific Advisory Board	no data	データなし	データなし
Björn Nilsson	Member of Scientific Advisory Board	no data	データなし	データなし
Mats Thoren	Independent Director	4.5yrs	SEK 435.00k	0.00026% SEK 787.4
Eva Nilsagard	Independent Director	5.5yrs	SEK 460.00k	0.00026% SEK 787.4
Gunnar Von Heijne	Member of Scientific Advisory Board	no data	データなし	データなし
Joen Luirink	Member of Scientific Advisory Board	no data	データなし	データなし
David Drew	Member of Scientific Advisory Board	no data	データなし	データなし
Kirsti Gjellan	Independent Director	2.5yrs	SEK 385.00k	0.00016% SEK 484.5
Anders Tullgren	Independent Chairman of the Board	6.6yrs	SEK 820.00k	0.0046% SEK 14.0k
Kristoffer Bissessar	Independent Director	less than a year	データなし	データなし

4.5yrs

平均在職期間

61yo

平均年齢

経験豊富なボード: XBRANEの取締役会は経験豊富であると考えられます ( 4.5年の平均在任期間)。

Xbrane Biopharma マネジメント

マネジメント 基準チェック /44

主要情報

経営陣の近況

Xbrane Biopharma AB (publ), Annual General Meeting, May 05, 2025

Xbrane Biopharma AB (Publ) Appoints Kristoffer Bissessar Was Elected as New Director

Xbrane Biopharma AB (Publ) Announces Appointment of Nomination Committee

Xbrane Biopharma AB (Publ) Presents Nomination Committee

Chief Executive Officer recently sold kr272k worth of stock

Chief Executive Officer recently bought kr150k worth of stock

Recent updates

New major risk - Financial position

Xbrane Biopharma AB (publ), Annual General Meeting, May 05, 2025

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

Xbrane Biopharma AB (publ) to Report Q1, 2025 Results on May 08, 2025

Xbrane Biopharma AB (publ) to Report Fiscal Year 2024 Results on Feb 21, 2025

Xbrane Biopharma AB (publ) to Report Fiscal Year 2024 Results on Feb 21, 2025

Even With A 30% Surge, Cautious Investors Are Not Rewarding Xbrane Biopharma AB (publ)'s (STO:XBRANE) Performance Completely

Xbrane Provides Update from Scientific Advice with US FDA on Xdivane™ (Opdivo® Biosimilar Candidate)

Consensus EPS estimates upgraded to kr0.095 loss

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Market Cool On Xbrane Biopharma AB (publ)'s (STO:XBRANE) Revenues Pushing Shares 34% Lower

Market Might Still Lack Some Conviction On Xbrane Biopharma AB (publ) (STO:XBRANE) Even After 32% Share Price Boost

First quarter 2024 earnings: Revenues miss analyst expectations

Xbrane Biopharma AB (publ) to Report Q2, 2024 Results on Aug 28, 2024

Xbrane Biopharma AB (Publ) Appoints Kristoffer Bissessar Was Elected as New Director

Consensus EPS estimates fall by 35%

New minor risk - Financial position

New major risk - Shareholder dilution

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

New major risk - Market cap size

Xbrane Biopharma AB (Publ) Announces Appointment of Nomination Committee

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Xbrane Biopharma AB (publ) Focuses on Development Portfolio and Introduces A Cost-Savings Scheme

Xbrane Biopharma AB (publ) to Report First Half, 2024 Results on Jul 17, 2024

Xbrane Biopharma AB (Publ) Presents Nomination Committee

Chief Executive Officer recently sold kr272k worth of stock

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Consensus revenue estimates fall by 28%

Forecast breakeven date pushed back to 2025

Xbrane Biopharma AB (publ) to Report Fiscal Year 2023 Results on Mar 27, 2024

Price target increased by 37% to kr219

Consensus revenue estimates increase by 14%, EPS downgraded

Price target increased by 13% to kr253

New major risk - Financial position

Chief Executive Officer recently bought kr150k worth of stock

COO, Head of Biosimilars & Deputy CEO recently bought kr817k worth of stock

Xbrane Biopharma AB (publ) to Report Fiscal Year 2023 Results on Feb 29, 2024

CFO & Head of Investor Relations recently bought kr236k worth of stock

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Insufficient new directors

Full year 2022 earnings: EPS and revenues miss analyst expectations

Consensus revenue estimates decrease by 15%

Now 22% undervalued

Xbrane Biopharma AB (publ) to Report Q1, 2023 Results on May 04, 2023

Insider recently bought kr156k worth of stock

Chief Executive Officer recently bought kr175k worth of stock

Xbrane Provides an Update on Ranibizumab Biosimilar Candidate FDA Filing

Forecast breakeven date pushed back to 2024

Price target increased to kr173

STADA Arzneimittel AG and Xbrane Biopharma AB Secures EU Approval for Ximluci (Ranibizumab) Biosimilar Referencing Lucentis

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Xbrane Biopharma AB (publ) to Report First Half, 2023 Results on Aug 31, 2023

STADA Arzneimittel AG and Xbrane Biopharma AB (publ) Announce European Medicines Agency’s Committee for Medicinal Products for Human Use Adopts Positive Opinion for Ximluci

Xbrane Biopharma AB (publ), Annual General Meeting, May 04, 2023

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Xbrane Biopharma AB (publ) to Report Q1, 2023 Results on May 31, 2023

Xbrane Biopharma AB (publ) to Report Fiscal Year 2022 Final Results on Mar 31, 2023

Xbrane Provides Update on Ranibizumab Biosimilar Candidate FDA Filing

Chief Executive Officer recently sold kr1.0m worth of stock

An unknown buyer acquired an unknown minority stake in Xbrane Biopharma AB (publ) (OM:XBRANE) from Martin Amark and Siavash Bashiri.

Head of Regulatory Affairs recently bought kr104k worth of stock

Chief Technology Officer recently bought kr699k worth of stock

Is Xbrane Biopharma (STO:XBRANE) In A Good Position To Deliver On Growth Plans?

Xbrane Biopharma AB (publ) Provides Update on Ranibizumab Biosimilar Candidate FDA Filing

Price target increased to kr235

Chief Executive Officer recently sold kr496k worth of stock

Xbrane Biopharma AB (Publ) Announces Positive Top-Line Results from the Pivotal Phase III Equivalence Trial for Xlucane™ - A Biosimilar Candidate to Lucentis

Xbrane Biopharma AB (publ)(OM:XBRANE) dropped from OMX Nordic Small Cap Index

We Think Xbrane Biopharma (STO:XBRANE) Needs To Drive Business Growth Carefully

マネジメント基準チェック /44